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Background: Lung cancer is the leading cause of cancer-related death in the world, with metastasis as the main
reason for the mortality. CELF1 is an RNA-binding protein controlling the post-transcriptional regulation of genes
related to cell survival. As yet, there is little knowledge of CELF1 expression and biological function in lung cancer.
This study investigated the expression levels of CELF1 in lung cancer tissues and the biological function of CELF1 in
lung cancer cells.
Methods: CELF1 mRNA expression was determined in lung cancer and normal tissues, and the relationship
between the expression level of CELF1 and clinicopathological parameters was evaluated. The biological function of
CELF1 in A549 and H1299 lung cancer cell lines growth was examined.
Results: The expression of CELF1 was higher in human lung cancer tissues compared with the normal lung tissue.
Lentiviral-mediated transfection of CELF1 siRNA effectively silenced the expression of CELF1 in both A549 and
H1299 cells. Moreover, CELF1 knockdown markedly reduced the survival rate of lung cancer cells. Colony formation
assays revealed a reduction in the number and size of lung cancer cell colonies from CELF1 knockdown.
Conclusion: These results indicated that CELF1 may have significant roles in the progression of lung cancer, and
suggested that siRNA mediated silencing of CELF1 could be an effective tool in lung cancer treatment.
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Lung cancer is one of the leading causes of cancer-
related deaths worldwide [1]. Studies have shown that
the genes and target proteins involved in lung cancer
function in cell proliferation [2], apoptosis [3], and
angiogenesis [4] pathways. Identifying a mechanism that
inhibits the growth of lung cancer metastasis would be
useful in developing potential treatments for lung can-
cer. Veale D et al. first reported the epidermal growth
factor receptor (EGFR) was associated with spread of
human non-small cell lung cancer and might be a poten-
tial therapeutic target in many carcinomas [5]. Now, the
EGFR superfamily is well known to promote cancer cell* Correspondence: chengjinfeng123@163.com
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reproduction in any medium, provided the orgrowth, and has become a therapeutic target for lung
cancer and changed the lung cancer treatment model.
By exploring new cancer-related genes and clearly iden-
tifying the roles of these genes in tumor development
and progression, not only can we obtain a deeper under-
standing of the nature of tumors, but we can also dis-
cover new tumor therapeutic targets.
The CELF (CUGBP and Etr-like factors) family pro-
teins are major sequence-specific RNA binding proteins
that control alternative splicing and mRNA translation
and stability [6,7]. Some reports have demonstrated that
CELF1 protein regulates pre-mRNA alternative splicing
and is involved in mRNA editing and translation [8-10].
Whether the expression of the CELF1 gene is related
to the proliferation of human lung cancer has not
been investigated.
Here we investigated the relationship between CELF1
expression and lung cancer clinicopathological factors at. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CELF1 on lung cancer cell growth at the cellular level.
Results
Expression of CELF1 in lung cancer tissues
To evaluate the levels of CELF1 expression in lung can-
cer tissues and normal tissues, real time PCR was per-
formed in 10 lung cancer tissues and 10 normal tissues.
Results showed that the relative expression levels of
CELF1 were higher in lung cancer tissues compared with
the normal tissues (Figure 1A and Table 1). Moreover,
the expression levels of CELF1 in lung cancer tumors
varied depending on tumor grade. CELF1 expression
levels were higher in low-grade cancers compared with
high-grade cancers (Figure 1B). A higher expression
level of CELF1 was observed in patients with the in-
crease of T stage, indicating that when tumors begin to
grow larger, gradually some other mechanism(s) may
play a more important role to promote cancer cell
growth, so the CELF1 expression level had some de-
crease. Furthermore, comparison of the survival rate ofFigure 1 Expression levels of CELF1 in lung cancer tissues. (A) Express
lung tissues analyzed by real time PCR. (B) Expression of CELF1 in lung can
the survival rate of patients with N1 and N2 lymph node metastasis and w
levels of CELF1 expression. The values represents the mean from three inde
compared with controls.patients with N1 and N2 lymph node metastasis and
without lymph node metastasis showed that the survival
rates were significantly higher in the absence of lymph
node metastasis (Figure 1C). In comparing the survival
rate with CELF1 expression levels, no significant dif-
ference in survival rate was observed between patients
with higher CELF1 expression and lower expression
(Figure 1D). Together these data indicate that CELF1 ex-
pression is not related to postoperative survival in lung
cancer patients.
Effect of CELF1 siRNA on the expression levels of CELF1
in lung cancer cells
Next, CELF1 mRNA and protein levels in A549 and
H1299 lung cancer cells were evaluated by real time
PCR and western blot, respectively. As shown in Figure 2,
both gene and protein expression of CELF1 were detected
in A549 and H1299 cells. The CELF1expressing lung can-
cer cells were then infected with lentivirus containing
CELF1 shRNA or non-silencing control shRNA, and suc-
cessful infection was confirmed by green fluorescence ofion levels of CELF1 in 10 lung cancer tissues compared with normal
cers at different stages analyzed by real time PCR. (C) Comparison of
ithout lymph node metastasis. (D) Comparison of the survival rate with
pendent experiments; bars represent SD. *P < 0.05, **P < 0.01
Table 1 Expression level of CELF1 in lung carcinoma and
relationship to clinicopathological parameters
Variable Case no. CELF1 expression (RQ: 2-ΔΔCT) P value
Median Mean ± SEM
Gender
Male 41 1.1090 1.2458 ± 0.9115 0.183
Female 12 0.7252 0.8938 ± 103.53
Age
≤ 60.5 32 0.9000 1.0103 ± 0.8746 0.118
> 60.5 21 0.1164 1.4035 ± 1.4948
Venous invasion
Negative 40 1.0274 1.2302 ± 1.2217 0.251
Positive 13 0.5492 0.9687 ± 0.9781
T stage
T1 7 1.5105 1.396 ± 1.1033 0.041
T2 21 1.2776 1.5178 ± 1.2898
T3 17 0.6242 0.8040 ± 0.7079
T4 8 0.3816 0.8109 ± 1.4910
N stage
N0 25 0.6242 0.9983 ± 1.1184 0.251
N1 11 1.3165 1.4731 ± 1.4334
N2 17 1.1164 1.2142 ± 1.0611
Lymph node status
N0 25 0.6242 0.9983 ± 1.1184 0.164
N1 + N2 28 1.2321 1.3159 ± 1.2020
TNM stage
Ia 4 1.2109 1.4055 ± 1.3481 0.089
Ib 6 1.2500 1.4397 ± 0.9834
IIa 5 1.3322 2.1861 ± 1.7131
IIb 13 0.6242 0.7331 ± 0.5595
IIIa 23 0.6624 1.1535 ± 1.2526
IIIb 2 0.2747 0.2747 ± 0.3882
Differentiation
Well 6 1.0545 0.8122 ± 0.5568 0.256
Moderate 28 0.9000 1.1866 ± 1.1315
Poor 19 1.0548 1.2476 ± 1.3613
Compared case
Tumor tissue 10 1.5263 1.9005 ± 1.4382 0.012
Normal tissue 10 0.2509 0.4579 ± 0.4761
Wu et al. Cancer Cell International 2013, 13:115 Page 3 of 8
http://www.cancerci.com/content/13/1/115infected cells (Figure 3A and B). Fluorescence analysis
showed that the lentiviral infection rate was higher in
H1299 cells than in A549 cells. Infection of cells with
lentivirus containing CELF1 shRNA significantly reduced
CELF1 gene and protein expression levels in both A549
and H1299 cells (Figure 3C-F). In contrast, the non-
silencing siRNA infection had no effect on CELF1 levels,confirming that CELF1 expression levels were reduced
specifically from CELF1 siRNA.
Effect of CELF1 knockdown on the survival of lung cancer
cells
The effect of CELF1 knockdown on lung cancer cell sur-
vival was analyzed using a MTT assay performed over a
five-day time course. In both cell lines, significant differ-
ences in cell survival were not observed until three days
after infection. From the 4th day of infection onwards,
significant differences in cell survival were observed in
both cell lines. The survival rate of CELF1 knockdown
cells was markedly (P < 0.0001) reduced at the 5th day of
infection compared with the non-infected and control
siRNA infected A549 and H1299 cells (Figure 4). The re-
duction in cell survival due to CELF1 knockdown was
higher in A549 cells than in H1299 cells.
Effect of CELF1 knockdown on the colony forming ability
of lung cancer cells
Lung cancer cells tend to form large cell colonies while
in culture; therefore, we next evaluated the effect of
CELF1 silencing on the colony forming ability of lung
cancer cells. As shown in Figure 5A and B, the size of
colonies in CELF1-silenced A549 and H1299 cells was
markedly reduced compared with the control groups.
Similarly, the number of colonies was also significantly
(P < 0.001) reduced with the CELF1 gene knockdown.
Together these results indicate that CELF1 plays an
important role in the growth progression of lung can-
cer cells.
Discussion
With increasing mortality rates, lung carcinoma has
already become the leading cause of cancer mortality
in the world [11]. Many genes are subjected to post-
transcriptional regulation via control of the rate of
mRNA turnover for transcripts bearing destabilizing cis-
elements [12]. Among the very few regulatory factors
identified thus far, CELF1 regulates post-transcriptional
gene expression by facilitating alternative splicing, trans-
lation [13], and mRNA degradation, and it functions by
binding directly to RNA [14]. Rattenbacher et al. identi-
fied the CELF1 gene and its target proteins as a critical
posttranscriptional regulatory network that may play a
role in the development of cancer [8]. In addition to re-
ports of involvement in breast cancer and leukemia de-
velopment, the CELF1 gene may also play a significant
role in tumorigenesis and the deterioration of certain tu-
mors [15], which is also confirmed by the results in our
present study.
Timchenko et al. first identified CELF1 function in the
regulation of translation of C/EBP beta isoforms [6].
Subsequent research demonstrated that members of this
Figure 2 Expression levels of CELF1 in lung cancer cells. (A). Expression levels of CELF1 in A549 and H1299 cells analyzed by real time PCR.
(B). Protein expression levels of CELF1 in A549 and H1299 cells analyzed by western blotting. The values represents the mean from three
independent experiments; bars represent SD. *P < 0.05, **P < 0.01 compared with controls.
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and may also be involved in mRNA editing and transla-
tion [16]. The CELF1 gene may play a role in myotonic
dystrophy type 1 (DM1) via interactions with the dys-
trophia myotonica-protein kinase (DMPK) gene [10]. A
previous report identified a correlation between the ex-
pression of CELF1 and human lung cancer [17]. How-
ever, the cellular mechanism underlying how the CELF1
gene causes this phenomenon has not been clarified. To-
gether these findings implicate possible involvement of
the CELF1 gene in cell growth. So far there is no litera-
ture reporting the biological function of CELF1 gene in
lung cancer cell. We speculate that CELF1 may also play
an important role in lung cancer proliferation.
Our research primarily focused on the effect of CELF1
knockdown on the viability of lung cancer cells. As
shown in the results, the expression of CELF1 was higherFigure 3 Knockdown of CELF1 gene in lung cancer cells. (A, B) Infectio
H1299 (B) cells. The efficiency was analyzed by fluorescence microscopic a
of CELF1 in normal cells, CELF1-silenced cells and non-silencing lentivirus in
expression levels of CELF1 protein in normal cells, CELF1-silenced cells and
The values represent the mean from three independent experiments; barsin human lung cancer tissues compared with normal tis-
sues. Moreover, A549 and H1299 lung cancer cells also
exhibited CELF1 expression in mRNA and protein level.
Lentiviral-mediated delivery of CELF1 silencing siRNA
significantly inhibited these upregulated levels of CELF1
expression, demonstrating that the CELF1 knockdown
method was successful. Further in vivo studies should be
performed to confirm the use of this siRNA method as a
potential therapeutic tool.
Interestingly, upon knockdown of CELF1, the survival
rates and colony forming ability of lung cancer cells were
markedly reduced, indicating pivotal roles of CELF1 in the
survival of lung cancer cells. Reports in the literature have
suggested that upregulation of CELF1 increased the
turnover of oncogenes related to the proliferation of
lung cancer cells [7,9,18]. Hence, in the absence of CELF1,
the turnover of possible oncogenes could presumablyn efficiency of lentivirus containing CELF1 siRNA in A549 (A) and
nalysis of infected cells. (C, D) The comparative gene expression levels
fected cells analyzed by real time PCR. (E, F). The comparative
non-silencing lentivirus infected cells analyzed by western blotting.
represent SD.
Figure 4 Effect of CELF1 gene knockdown on the proliferation of lung cancer cells. Proliferation of A549 (A) and A1299 (B) cells were
treated as indicated and measured by MTT assay. The values represents the mean from three independent experiments; bars represent SD.
***P < 0.001 compared with controls.
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creased capacity of proliferation and colony formation.
Our study showed that CELF1 is overexpressed in lung
cancer tissue on RNA level compared with the normal
lung tissue and tumor grades had relationship with CELF1
expression level, which is line with the hypothesis men-
tioned above.
From these results, we can conclude that CELF1 can
affect the growth of lung cancer cells and plays an im-
portant role in the tumor development process. Further
research on the molecular mechanisms of the CELF1
gene is required, particularly in identifying CELF1-
interacting proteins, elucidating the molecular mecha-
nisms underlying its biological effects, and determiningFigure 5 Effect of CELF1 gene knockdown on the colony forming abi
bright field and fluorescence microscopy. The colonies were stained with G
normal, CELF1-silenced and non-silenced lung cancer cells. (C, D) The numbe
cells. The values represents the mean from three independent experiments; bwhether it plays a guiding role in the treatment of lung
cancer.
Conclusion
In summary, CELF1 may have significant roles in the
progression of lung carcinoma. The CELF1 siRNA me-
thod has emerged as a potentially powerful tool for can-
cer therapeutics in silencing genes responsible for cancer
progression and tumorigenesis.
Materials and methods
Human specimens and reagents
Fifty-three pulmonary cancer samples of fresh frozen tis-
sue were acquired from the Department of Thoraciclity of lung cancer cells. (A, B) The cancer cell colonies under light,
iemsa staining. The images show comparison of the size of colonies in
r of colonies in normal, CELF1-silenced and non-silenced lung cancer
ars represent SD. **P < 0.01, ***P < 0.001 compared with controls.
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the Ethical Committee. Written consent statements were
obtained from all patients before operation. None of the
patients received any neoadjuvant therapy prior to
surgery. The tissues were collected immediately after
surgical resection at the Beijing Cancer Hospital and
stored at the Tissue Bank of Peking University Oncology
School. Clinicopathological characteristics of the tumors
were defined according to the TNM staging system
criteria of UICC. Clinicopathological factors are shown in
Table 1.
AgeI, EcoRI, and SYBRGreen Master Mix Kits were
purchased from TaKaRa (Dalian, China). pHelper1.0,
pHelper 2.0, and pGCSIL-GFP plasmids were purchased
from Genechem Co. Ltd (Shanghai, China). The RNeasy
Midi Kit was from Qiagen (Valencia, CA, USA). Dulbec-
co’s modified Eagle’s medium (DMEM), Roswell Park
Memorial Institute 1640 (RPMI 1640) and fetal bovine
serum (FBS) were obtained from Hyclone (Logan, UT,
USA). Lipofectamine2000, TRIzol and SuperScriptII re-
verse transcriptase were purchased from Invitrogen
(Carlsbad, CA, USA). All other chemicals were obtained
from Sigma (St. Louis, MO, USA). The following anti-
bodies were obtained from Santa Cruz: anti-CELF1
(1:1000 dilution), anti-GAPDH (glyceraldehyde-3-phosphate
dehydrogenase, 1:3000 dilution) and anti-mouse HRP
(1:5000 dilution).
Cell culture
Human lung cancer cells (A549 and H1299) and human
embryonic kidney (HEK) 293 T cell lines were obtained
from the cell bank of Shanghai Institute of Cell Biology.
A549 and 293 T cells were maintained in DMEM sup-
plemented with 10% heat-inactivated FBS and penicillin/
streptomycin at 37°C in a humidified atmosphere of 5%
CO2. H1299 cells were maintained in RPMI 1640 me-
dium supplemented with 10% heat-inactivated FBS and
penicillin/streptomycin at 37°C in a humidified atmos-
phere of 5% CO2.
Construction of CELF1 shRNA-containing lentivirus and
infection
The sequences of CELF1 siRNA and non-silencing con-




AGAATTTTTTTAAT-3′, respectively. The nucleotide
sequences were inserted into the plasmid through the
pFH-L vector (Shanghai Hollybio, China) and the gen-
erated lentiviral-based shRNA-expressing vectors were
confirmed by DNA sequencing. Lentiviruses were genera-
ted by transfection of 293 T cells at 80% confluence with
generated plasmids. The cells were starved for 2 h beforetransfection, and pFH-L-shCELF1 or -shCTRL and the
packaging vector carriers pVSVG-I and PCMVΔR8.92
were transfected into cells using Lipofectamine 2000. The
supernatant was collected 48 h after transfection and len-
tiviral particles were harvested by ultracentrifugation
(4000 g) at 4°C for 10 min. The collected virus particles
were filtered through a 45 μM filter and the filtrate was
centrifuged (4000 g at 4°C) for 15 min to collect the viral
concentrate.
A549 and H1299 cancer cells were then infected with
CELF1 shRNA- or control shRNA-expressing lentivi-
ruses at a MOI of 30 for A549 cells or MOI of 15 for
H1299 cells. The cells were seeded (5 × 104 cells per
well) in six-well plates, and after 24 h of incubation, the
culture medium was replaced with Opti-MEM medium
containing the appropriate amount of the virus. The
cells were then incubated with the virus for another
48 h. Successful transfection was confirmed by observa-
tion through a fluorescence microscope (Leica, Germany)
for expression of green fluorescence protein.
Real-time PCR analysis
RNA was obtained using the Total RNA Isolation Rea-
gent (ABgene™) according to the manufacturer’s instruc-
tions (Abgene, Surrey, UK). Total RNA was converted to
cDNA using DuraScript™, a commercial reverse tran-
scription kit from Sigma Aldrich. Real-time quantitative
PCR analysis for the RNA extracted from lung cancer
tissues and cultured lung cancer cells was performed
using the SYBR Green Master Mix Kit (Applied Biosys-
tems, Foster City, CA). In brief, each PCR reaction mix-
ture contained 10 μl of 2 × SYBR Green Master Mix,
0.4 μl of sense and antisense primers (2.5 μM) and 10 ng
of cDNA. Reactions were run for 40 cycles, including de-
naturation at 95°C for 10 min and annealing at 60°C for
1 min in a total volume of 20 μl using an ABI 7500 Real
Time PCR platform. The primer sequences for PCR
amplification of the CELF1 gene were 5′-ACCTGTTC
ATCTACCACCTG-3′ and 5′-GGCTTGCTGTCATTC
TTCG-3′. Primer sequences for the internal control
GAPDH were 5′-GACCCCTTCATTGACCTCAAC-3′
and 5′-CTTCTCCATGGTGGTGAAGA-3′. Relative gene
expression levels were calculated using 2-ΔΔCTanalysis.
Western blot analysis
A549 and H1299 cells were infected with the lentivirus
containing CELF1 shRNA and control shRNA for five
days. The cells were then washed with cold PBS and
lysed with radio-immune precipitation assay (RIPA) buf-
fer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS) containing phenyl-
methylsulfonyl fluoride (PMSF) (1 mM) and protease in-
hibitors (2 μg/ml; Protease Inhibitor Cocktail Set III,
Calbiochem) on ice for 30 min. The supernatant was
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15 min) and the protein content was measured by the
Lowry method. The protein concentration of each sam-
ple was adjusted to 2 μg/μl and a 20 μl volume was
mixed with 2 × SDS sample buffer (100 mM Tris–HCl,
pH 6.8, 10 mM EDTA, 4% SDS, 10% glycine) and se-
parated by electrophoresis on a 10% SDS-PAGE gel
at 50 V for 3 h. The gel was transferred to a PVDF
membrane at 300 mA for 1.5 h, and proteins were
detected after primary antibody treatment overnight
at 4°C and secondary antibody treatment for 2 h at
room temperature using an Amersham ECL kit (GE
Healthcare, UK) and exposure to X-ray film. The
bands obtained were quantified with an Image Quant
densitometric scanner (Molecular Dynamics, Amersham
Biosciences).
MTT analysis
For the cell viability analysis, A549 and H1299 cells were
first seeded (2 × 103 cells/well) into a 96-well plate and
infected with CELF1 silencing or non-silencing siRNA-
containing lentivirus for 72 h. Following infection, 20 μl
of MTT solution (5 mg/ml) was added to each well and
cells were incubated at 37°C for 4 h. The medium and
MTT from the wells was removed and 200 μl of DMSO
was added to each well. The optical density was mea-
sured using a microplate reader at 490 nm. Experiments
were performed in triplicate.
Colony formation assay
Lung cancer cells seeded in six-well plates (2 × 102 cells/
well) were infected with CELF1 silencing and non-
silencing siRNA-containing lentivirus for 72 h. The cells
were continuously incubated, and medium was replaced
with new medium every three days until 8 days of cul-
ture. The cells were then washed with PBS and fixed
with 4% paraformaldehyde. The fixed cells were stained
with freshly prepared diluted Giemsa stain for 20 min.
The cells were washed with double distilled water and
colonies were counted using a fluorescence microscope.
Consent
Written informed consent was obtained from the patients
before operation.
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